acapatamab (AMG 160)

BsAbs are a promising therapeutic strategy for mCRPC, with potential to improve outcomes in this poorly treatable disease. Addressing challenges (toxicity, tumor microenvironment, response durability) via research and trials is key to unlocking their full potential. Future research should focus on optimizing constructs, exploring novel targets, and developing combination therapies to advance BsAbs in prostate cancer.

P1, N=212, Terminated, Amgen | Completed --> Terminated; Sponsor Decision

P1, N=3, Terminated, Amgen | Phase classification: P1b --> P1

P1/2, N=65, Terminated, Amgen | Active, not recruiting --> Terminated; Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.

P1, N=212, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jul 2023 | Trial primary completion date: May 2025 --> Jul 2023

P1/2, N=65, Active, not recruiting, Amgen | N=136 --> 65

Activation of autologous T cells within the tumor slices was assayed by flow cytometry, and secretion of cytokines into culture supernatants was measured by Meso Scale Discovery (MSD). Together these data suggest that antitumor efficacy of the AMG 160 HLE BiTE immune therapy can be increased by co-treatment with anti-PD-1. These data provide a rationale for evaluating this combination in future clinical studies. Research Funding: Amgen Inc.

Activation of autologous T cells within the tumor slices was assayed by flow cytometry, and secretion of cytokines into culture supernatants was measured by Meso Scale Discovery (MSD). Together these data suggest that antitumor efficacy of the AMG 160 HLE BiTE immune therapy can be increased by co-treatment with anti-PD-1. These data provide a rationale for evaluating this combination in future clinical studies. Research Funding: Amgen Inc.